TRIIM-X
Phase 1- Indications
- Immunosenescence, Age-related immune system decline
Company intelligence / Profile preview
Intervene Immune, Inc.
Torrance, California, United Statesinterveneimmune.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Currently conducting the TRIIM-X trial, a Phase 2 clinical study evaluating a personalized combination treatment regimen for thymus regeneration. The study evaluates biomarkers for epigenetic aging and immunosenescence, as well as clinical measures for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and infectious diseases.
- Therapeutic areas
- OtherImmunology
- Modalities
- Pharmaceutical combinations (human growth hormone, DHEA, metformin)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Intervene Immune, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intervene Immune, Inc..